FINEARTS-HF
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF≥ 40%)
- Stadium
- klaar
- Middel
- finerenone
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 25 september 2020
- Last Patient In
- 10 januari 2023
- Last Patient Last Visit
- 5 juni 2024
National Lead
dr. G.C.M. Linssen
Cardioloog
Contact Kantoor
